MoneyWorks4Me

LUPIN informs about press release

23 Jun 2023 Evaluate
LUPIN has informed that it enclosed a Press release regarding launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. This is disclosure pursuant to Regulation 30 of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Peers